The role of interferon-gamma in the immunotherapy of neuroblastoma.
Handgretinger
R
R
Children's University Hospital, Dept. of Haematology/Oncology, Tuebingen, FRG.
Bruchelt
G
G
Daurer
B
B
Lang
P
P
Herter
M
M
Dopfer
R
R
Müller
B
B
Reisfeld
R A
RA
Treuner
J
J
Niethammer
D
D
D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D014408:Biomarkers, Tumor / Q000097:blood; D002648:Child; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D007371:Interferon-gamma / Q000494:pharmacology* / Q000502:physiology*; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D009000:Monocytes / Q000187:drug effects / Q000276:immunology*; D009447:Neuroblastoma / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use
D014408:Biomarkers, Tumor; D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma; D015088:2',5'-Oligoadenylate Synthetase